Skip to content

To relieve acute muscle and bone pain with GS/CM/RR/O-1

A randomized placebo controlled trial to evaluate analgesic and anti inflammatory effects for Musculo skeletal disorders. - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/105726
Enrollment
60
Registered
2026-03-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M00-M99- Diseases of the musculoskeletal system and connective tissue

Interventions

None listed

Sponsors

Greenspace
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects of both genders with age group between 15-85 years 2. Subjects with Musculo-skeletal pain due to idiopathic, systemic or trauma for more than 24 hours. 3. Pain of VAS scale between 5-44mm (Mild pain) to 45-74 mm (Moderate pain) 4. Subjects who are willing to give written consent.

Exclusion criteria

Exclusion criteria: 1.Subjects suffering from co-morbidities like rheumatoid arthritis, gouty arthritis or psoriatic arthritis. 2.Participants with the history of fracture of the joint. 3.Subjects under cortico-steroids, NSAIDS or systemic analgesics. 4.Subjects with gross disability having difficulty performing their routine chores. 5.Hypersensitive to any of the ingredients of the product. 6.Open wounds or injury at the site of application of oil. 7.Any other condition which the investigator feels will jeopardize the trial.

Design outcomes

Primary

MeasureTime frame
1.Change in pain intensity measured through Visual Analogue Scale (VAS) scale from baseline to 15 days. 2.Change in functional ability measured through Brief Pain Inventory questionnaire (BPI) from baseline to 15 days. 3.Average time taken for reducing the pain and duration of effectiveness of the oil. Timepoint: Day 0, Day 8 and Day 15

Secondary

MeasureTime frame
1. Change in swelling, tenderness or stiffness as per gradation (if present) 2. Change in PEG (Pain, enjoyment, general activity) tool from baseline to 15 days 3. Improvement in sleep from baseline to 15 days 4. Any changes in pigmentation if present 5. Local adverse events (redness, itching, burning)/ tolerability of the product 6. Serious adverse events Timepoint: Day 0 and Day 15

Countries

India

Contacts

Public ContactDr Gangothri S Kumar

Greenspace

dr.gangothri@greenspaceherbs.com7795525107

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026